linjc16/ctgov huggingface dataset:
Minocycline Treatment in Acute Hemorrhagic Stroke

Study Overview
=================
Brief Summary
-----------------
The investigators will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.

Detailed Description
-----------------
Minocycline, a semisynthetic second generation derivative of tetracycline, was shown to have a clear beneficial neuroprotective effect in animal models of multiple sclerosis, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Animal models provide promising evidence of minocycline's ability to improve outcomes in an animal stroke model. In light of these findings, we will perform a double blind controlled study to investigate the efficacy of oral administration of 200 mg minocycline, on the neurological and functional outcome after acute hemorrhagic stroke and the effect on blood brain barrier permeability.

Official Title
-----------------
Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability

Conditions
-----------------
Poor Performance Status

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute hemorrhagic stroke age > 18 NIHSS score > 5 onset of stroke 6 to 24 hours prior to beginning of treatment. Patients, who arrived within 0 to 6 hours post stroke, were treated with other medications according to the best accepted medical treatment guidelines. Exclusion Criteria: Evidence of other disease of the central nervous system, including brain tumor, demyelinating disease, inflammatory disease of the central nervous system, craniotomy in the past, severe brain injuries and benign intracranial hypertension pre-existing neurological disability known allergic response to tetracyclines acute or chronic renal failure pre-existing infectious disease requiring antibiotic therapy swallowing difficulties

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Fluorescence-navigated Thoracoscopy for Pulmonary Segmentectomy

Study Overview
=================
Brief Summary
-----------------
Recently developed fluorescence-navigated thoracoscopy with indocyanine green (ICG) is being used for various kinds of pulmonary surgery, and several studies have reported the application of this novel technique in demarcation of the intersegmental border for segmentectomy. This study is performed prospectively to find out, for the first time, the optimal dosage of ICG in human body to ensure safe and sustained imaging during segmentectomy.

Official Title
-----------------
Fluorescence-navigated Thoracoscopy for Pulmonary Segmentectomy

Conditions
-----------------
Pulmonary Segmentectomy

Intervention / Treatment
-----------------
* Procedure: Indocyanine Green Injection through Peripheral Vein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suitable for segmentectomy and signed informed consent Exclusion Criteria: Liver dysfunction. Allergic to indocyanine green. Can't tolerate thoracoscopic surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>0.6mg/kg of ICG, iv | Procedure: Indocyanine Green Injection through Peripheral Vein<br>* After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.<br>|
| Experimental: B<br>0.2mg/kg of ICG, iv | Procedure: Indocyanine Green Injection through Peripheral Vein<br>* After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Signal-to-background Ratio (SBR) of the Targeted and Non-targeted Segments | We use image analysis software ImageJ to evaluate the strength of luminosity in the targeted and non-target segments using intraoperative images and calculate signal-to-background-ratio. | Surgery |
The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms

Study Overview
=================
Brief Summary
-----------------
To prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.

Detailed Description
-----------------
The primary objective of this study is to prescribe oral domperidone for patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy

Official Title
-----------------
The Use Of Domperidone For The Relief Of Refractory Upper Gastrointestinal GI Symptoms

Conditions
-----------------
Gastroparesis

Intervention / Treatment
-----------------
* Drug: Domperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females who are 18 years of age or older Symptoms or manifestations secondary to Gastro esophageal reflux disease (GERD) (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy. Exclusion Criteria: i. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded. ii. Clinically significant bradycardia, sinus node dysfunction, or heart block. iii. Prolonged QTc (QTc>450 milliseconds for males, QTc>470 milliseconds for females) iv. Clinically significant electrolyte disorders. Gastrointestinal hemorrhage or obstruction. Presence of a prolactinoma (prolactin-releasing pituitary tumor). Pregnant or breast feedings female. Known allergy to domperidone

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparison of Ascorbic Acid and Grape Seed Extract in Oxidative Stress Induced by on Pump Heart Surgery

Study Overview
=================
Brief Summary
-----------------
Study aimed to compare the effect of grape seed extract and ascorbic acid in oxidative stress induced by on pump coronary artery by pass grafting surgery.

Detailed Description
-----------------
This study aimed to compare the effect of grape seed extract and ascorbic acid in oxidative stress induced by on pump coronary artery by pass grafting surgery. There are three groups in the study. 75 candidate of coronary artery by pass grafting surgery were assigned random allocation on the groups (25 in each group). Control GSE (100 mg/6h - PO, 24h before surgery) Vit C (25 mg/kg in pump circulation during surgery)

Official Title
-----------------
Effect of Ascorbic Acid and Grape Seed Extract Vitis Vinifera L. in Oxidative Stress Induced by on Pump Coronary Artery by Pass Grafting Surgery

Conditions
-----------------
CABG-Induced Oxidative Stress

Intervention / Treatment
-----------------
* Drug: GSE
* Drug: Vit C (Ascorbic Acid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Candidates for elective CABG surgery with pump for first time 3VD Exclusion Criteria: High risk patients Those who need another heart surgery beside CABG Urgent patients Diabetics Ischemic time more than 120 min
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>normal procedure of CABG | |
| Active Comparator: 2: GSE<br>100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h) | Drug: GSE<br>* grape seed extract (100 mg/6h), PO<br>* Other names: Grape Seed Extract;|
| Active Comparator: 3: Vit C<br>25 mg/kg through pump | Drug: Vit C (Ascorbic Acid)<br>* Vit C 25 mg/ kg<br>* Other names: Ascorbic Acid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LVEF |  | Before and after CABG | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Antioxidant Capacity (TAC) |  | Before ischemia, after ischemia, after reperfusion | 
| MDA |  | Before, middle and after CABG | 
| GTX |  | Before ischemia, after ischemia, after reperfusion | 
| SOD |  | Before ischemia, after ischemia, after reperfusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CABG, on pump, Grape seed extract, Vit C, Oxidative stress
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment in subjects with a history of allergic conjunctivitis

Official Title
-----------------
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With a History of Allergic Conjunctivitis

Conditions
-----------------
Allergic Conjunctivitis

Intervention / Treatment
-----------------
* Drug: Bromfenac
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of clinically active allergic conjunctivitis Agree to return for all required visits Agree to avoid disallowed meds Exclusion Criteria: Known hypersensitivity to bromfenac and salicylates

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bromfenac<br>Ophthalmic Solution | Drug: Bromfenac<br> <br> |
| Placebo Comparator: Placebo<br>Vehicle ophthalmic solution | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment of ocular itching |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment of chemosis, episcleral and ciliary hyperemia, ocular mucous discharge, eyelid swelling, foreign body sensation, nasal symptoms, and/or tearing |  |  |
Transcatheter Aortic Valve Intervention-Live Transmission

Study Overview
=================
Brief Summary
-----------------
The primary objective of this clinical trial is to evaluate safety of patients who underwent Transcatheter Aortic Valve Intervention (TAVI) during a live case or video-taped transmission as compared to those without procedure transmission.

Detailed Description
-----------------
A series of sites from outside the US, where the Edwards-Sapien and CoreValve devices are approved for commercial sale and implantation, will be recruited to retrospectively identify and extract in-hospital data of a patient who underwent TAVI during a live or video-taped procedure and a matched patient who underwent TAVI without transmission of the procedure.

Official Title
-----------------
Transcatheter Aortic Valve Intervention-Live Transmission (VERITAS)Study

Conditions
-----------------
Aortic Valve Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Cases Inclusion Criteria: Subjects > 18 years of age, male or female Subject had live case or video-taped transmission of TAVI procedure with: Edwards-Sapien transfemoral approach, Edwards-Sapien transapical approach, or CoreValve transfemoral approach Controls Inclusion Criteria: Subjects > 18 years of age, male or female Subject underwent TAVI without procedure transmission and had: Edwards-Sapien transfemoral approach, Edwards-Sapien transapical approach, or CoreValve transfemoral approach Subjects will be matched to Cases upon the following: STS SCORE +/- 2points Date of TAVI procedure +/- 4weeks The first attending for the TAVI procedure Access site for TAVI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TAVI live case or video-taped transmission<br> | |
| TAVI without transmission<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major complication defined as in hospital death, stroke, tamponade, valve embolization, coronary obstruction, renal failure requiring dialysis, and the need for a pacemaker. |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcatheter Aortic Valve Intervention (TAVI), Live case transmission
Machine Learning-Based Risk Profile Classification of Patients Undergoing Elective Heart Valve Surgery

Study Overview
=================
Brief Summary
-----------------
Machine learning methods potentially provide a highly accurate and detailed assessment of expected individual patient risk before elective cardiac surgery. Correct anticipation of this risk allows for improved counseling of patients and avoidance of possible complications. The investigators therefore investigate the benefit of modern machine learning methods in personalized risk prediction in patients undergoing elective heart valve surgery.

Detailed Description
-----------------
The investigators performe a monocentric retrospective study in patients who underwent elective heart valve surgery between January 1, 2008, and December 31, 2014 at our center. The investigators use random forests, artificial neural networks, and support vector machines to predict the 30-days mortality from a subset of demographic and preoperative parameters. Exclusion criteria were re-operation of the same patient, patients that needed anterograde cerebral perfusion due to aortic arch surgery, and patients with grown up congenital heart disease.

Official Title
-----------------
Machine Learning-Based Risk Profile Classification of Patients Undergoing Elective Heart Valve Surgery

Conditions
-----------------
Heart Valve Diseases, Surgery--Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: * Patients who underwent heart valve surgery of any kind between 2008-01-01 and 2014-12-31 were included. Exclusion Criteria: re-operation of the same patient patients that needed anterograde cerebral perfusion due to aortic arch surgery patients with grown-up congenital heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve for different prediction models | Three different predictions models will be used. | Patients will included from 01.01.2008 - 31.12.2014 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
random forests, heart valve surgery, support vector machines, artificial neural networks
Chiropractic Treatment of Arthrogenic Torticollis in Infants; a Retrospective Study on Outcome in 1000 Infants

Study Overview
=================
Brief Summary
-----------------
Patient data is collected from previously treated patients and entered into the Research Electronic Data Capture (REDCap).

Detailed Description
-----------------
Already collected patient data (1995-2013) from a privat practice, is screened and entered into a individually design REDCap form.

Official Title
-----------------
Chiropractic Treatment of Arthrogenic Torticollis in Infants; a Retrospective Study on Outcome in 1000 Infants

Conditions
-----------------
Arthrogenic Torticollis

Intervention / Treatment
-----------------
* Other: chiropractic treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: arthrogenic torticollis male or female age 3-12 month treatment was conducted between 01/1995-12/2013 Exclusion Criteria: uncompleted record decline of further use of patient data

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment outcome | Subjective treatment outcome after chiropractic care | 3-12 month of age |
Hemodynamic Monitoring With Mixed Venous Saturation

Study Overview
=================
Brief Summary
-----------------
In this study the investigators aim to evaluate the utility of a continuous mixed venous saturation monitoring compared to a clinical examination in a group of critically ill patients.

Detailed Description
-----------------
We will compare possible difference in terms of sensibility and specificity regarding the continuous mixed venous saturation monitoring compared to clinical examination in a group of critically ill patients.

Official Title
-----------------
Hemodynamic Monitoring. The Continuous Measurement of Mixed Venous Saturation Compared to Clinical Valuation: A Pilot Study

Conditions
-----------------
Critically Ill

Intervention / Treatment
-----------------
* Procedure: Mixed venous saturation monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients with a central venous catheter Exclusion criteria: Patients with pulmonary catheter

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | Procedure: Mixed venous saturation monitoring<br>* Mixed venous saturation monitoring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodynamic monitoring, Mixed venous saturation, Critically ill patients
Development of Three Dimensional Preoperative Planning System for the Osteosynthesis of Distal Humerus Fractures

Study Overview
=================
Brief Summary
-----------------
To reproduce anatomical reduction and appropriate implant placement/choices during osteosynthesis for elbow fractures, a 3D preoperative planning system was developed. To assess the utility of 3D digital preoperative planning for the osteosynthesis of distal humerus fractures, the reproducibility of implant reduction shapes and placements in patients with distal humerus fractures will be evaluated.

Detailed Description
-----------------
3D preoperative planning will be applied for four distal humerus fracture cases . The preoperative planning will be performed in order to determine the reduction, placement and choices of implants. After the operation, the accuracy of the reduction and implants choices and placements will be verified. The reductions will be evaluated with an angle between the diaphysis axis and a line connecting the medial epicondyle with the lateral epicondyle and an angle between the diaphysis axis and the articular surface in the coronal plane and distance between the anterior diaphysis and the anterior articular surface in the sagittal plane for the 3D images of distal humerus. The reproducibility will be evaluated by the differences of the parameters between pre- and post-operative images.

Official Title
-----------------
Development of Three Dimensional Preoperative Planning System for the Osteosynthesis of Distal Humerus Fractures

Conditions
-----------------
Distal Humerus Fracture

Intervention / Treatment
-----------------
* Device: Digital preoperative planning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Distal humerus fracture patients Exclusion Criteria: Patients with a previous history of traumatic injuries to the elbow

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: A case control study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Digital preoperative planning<br>To use digital preoperative planning software | Device: Digital preoperative planning<br>* Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction shape | Reduction shape parameter | 1 year | 
| Implant placement | Implant placement parametes | 1 year |